{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(3)"],"submitter":["Talaat KR"],"funding":["Intramural NIH HHS"],"pubmed_abstract":["<h4>Background</h4>The disease course of human immunodeficiency virus (HIV) is often altered by existing or newly acquired coincident infections.<h4>Methodology/principal findings</h4>To assess the influence of pre-existing Wuchereria bancrofti infection on HIV progression, we performed a case-controlled treatment study of HIV positive individuals with (FIL+) or without (FIL-) W. bancrofti infection. Twenty-eight HIV+/FIL+ and 51 matched HIV+/FIL- subjects were treated with a single dose of diethylcarbamazine and albendazole (DEC/Alb) and followed for a year at regular intervals. Sixteen of the HIV+/FIL+ subjects (54%) and 28 of the HIV+/FIL- controls (57%) were on antiretroviral therapy (ART) during the study. Following treatment, no differences were noted in clinical outcomes between the"],"journal":["PLoS neglected tropical diseases"],"pagination":["e0003622"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4368731"],"repository":["biostudies-literature"],"pubmed_title":["Treatment of W. bancrofti (Wb) in HIV/Wb coinfections in South India."],"pmcid":["PMC4368731"],"pubmed_authors":["Babu S","Arumugam J","Dhakshinamurthy K","Fay MP","Swaminathan S","Poongulali S","Gu W","Talaat KR","Sharma J","Srinivasan R","Kumarasamy N","Menon P","Nutman TB"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of W. bancrofti (Wb) in HIV/Wb coinfections in South India.","description":"<h4>Background</h4>The disease course of human immunodeficiency virus (HIV) is often altered by existing or newly acquired coincident infections.<h4>Methodology/principal findings</h4>To assess the influence of pre-existing Wuchereria bancrofti infection on HIV progression, we performed a case-controlled treatment study of HIV positive individuals with (FIL+) or without (FIL-) W. bancrofti infection. Twenty-eight HIV+/FIL+ and 51 matched HIV+/FIL- subjects were treated with a single dose of diethylcarbamazine and albendazole (DEC/Alb) and followed for a year at regular intervals. Sixteen of the HIV+/FIL+ subjects (54%) and 28 of the HIV+/FIL- controls (57%) were on antiretroviral therapy (ART) during the study. Following treatment, no differences were noted in clinical outcomes between the","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Mar","modification":"2025-05-18T13:17:48.625Z","creation":"2025-05-18T13:17:48.625Z"},"accession":"S-EPMC4368731","cross_references":{"pubmed":["25793933"],"doi":["10.1371/journal.pntd.0003622"]}}